Aug 2026· AJP - Renal Physiology· Vol 331, pp. F450 - F462· 0 citations
Medicine
TL;DR
It is demonstrated that the lipid droplet protein perilipin 2 (Plin2) was induced after cisplatin-induced AKI, with markedly greater induction in aged kidneys and distinct organ-specific patterns in the liver and heart.
Abstract
Cisplatin is a widely used chemotherapeutic agent, but acute kidney injury (AKI) remains its dose-limiting toxicity, particularly in older patients. In recent years, dysregulated lipid metabolism has emerged as a key driver of cisplatin nephrotoxicity; however, the underlying mechanisms and their modulation across ages remain incompletely understood. Here, we demonstrated that the lipid droplet protein perilipin 2 (Plin2) was induced after cisplatin-induced AKI, with markedly greater induction in aged kidneys and distinct organ-specific patterns in the liver and heart. Knockdown of Plin2 protected against cisplatin-induced AKI in young mice, as evidenced by reduced serum creatinine and blood urea nitrogen levels, attenuated morphological injury, decreased tubular cell apoptosis, and diminished inflammation, but failed to confer protection in aged mice. Proteomic profiling identified selective upregulation of 3-hydroxy-3-methylglutaryl-CoA synthase 2 (Hmgcs2), suggesting enhanced ketogenesis in Plin2-knockdown kidneys. Surprisingly, Plin2 knockdown did not significantly alter fatty acid oxidation and glycolytic pathways after AKI. Mechanistically, Plin2 interacts with sirtuin 5 (Sirt5) to regulate Hmgcs2 desuccinylation, impairing ketogenesis and tubular energy homeostasis to exacerbate AKI in an age-dependent manner.
It is demonstrated that PARP1 deficiency attenuates cisplatin-induced renal dysfunction, tubular injury, and inflammatory responses and the suppression of NF-κB activation and the COX-2/PGE2 response as features of this protective phenotype support a potential PARP1–NF-κB–COX-2/PGE2 signaling axis in cisplatin nephroto...
Findings indicate that PTE protects against Cis-AKI, at least in part, through suppression of the TLR4/MyD88/NF-κB signaling cascade, thereby mitigating inflammation, oxidative stress, and apoptosis.
Cisplatin-induced acute kidney injury (CI-AKI) is a common and severe complication in cancer patients undergoing chemotherapy, which can progress to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Ferroptosis and inflammation are critical pathological mechanisms underlying CI-AKI. Trilobatin (TLB),...
Yang Xiang, Die Zhang, Qiang-Fang Dai et al.· Food Science and Human Welln...· 0 citations
Background/Objectives: Cisplatin-induced acute kidney injury (AKI) is a major adverse complication restricting cisplatin-based chemotherapy. Ferroptosis contributes substantially to proximal tubular epithelial injury during AKI. This work aimed to explore the renoprotective effect of echinacoside (ECH) and its underlyi...
Li-Jia Chen, Ming-Jie Zhang, M. Chi et al.· Biomedicines· 0 citations
DAP attenuates inflammation and kidney injury in SA-AKI, accompanied by inhibition of non-canonical NF-κB signaling and enhanced autophagic activity and these findings suggest that DAP may represent a promising therapeutic candidate for SAAKI.
Zi-Gang Zhao, Chen Zhang, Xiao-Qiong Zhang et al.· Current Medicinal Chemistry· 0 citations
The epigenetic mechanisms driving the transition to ferroptosis in acute kidney injury (AKI) remain unclear. In this study, protein methyltransferase 5 (PRMT5) and its partner MEP50 were significantly upregulated in the renal tubules of AKI patients and murine models. Genetic silencing of PRMT5 via AAV-shRNA in vivo an...
Jia-Wen Lin, Jun-Xuan Fang, Tian-Jiao Cui et al.· Redox Biology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.